O4‐11‐02: The path to regulatory qualification of cerebrospinal fluid biomarkers as enrichment tools in clinical trials of patients with early Alzheimer's disease: For the coalition against major diseases
Year: 2015
Type: article
Source: Alzheimer s & Dementia
Authors: Hugo Marcel Vanderstichele, Diane Stephenson, Leslie M. Shaw, Maria Carrillo, Robert Umek, Hemaka Rajapakse, Johan Luthman, Holly Soares, Mark Forrest Gordon, Viswanath Devanarayan, Just Genius, Robert Berman, James Hendrix, Klaus Romero, June Kaplow, Brian Willis, Janice Hitchcock, Peng Yu, John Lawson, David Raunig, Richard Meibach, Kaori Ito, Laurel Beckett, Sebastiaan Engelborghs, Kaj Blennow, Robert A. Dean
Institutions: Ghent University Hospital, Critical Path Institute, University of Pennsylvania, Alzheimer's Association, Meso Scale Discovery (United States), Eisai (United States), Bristol-Myers Squibb (United States), Boehringer Ingelheim (United States), AbbVie (United States), Biohaven Pharmaceuticals (United States), Eli Lilly (United States), Fujirebio US (United States), Imperial Consultants, Novartis (United States), Pfizer (United States), University of California, Davis, University of Antwerp, University of Gothenburg
Language: English
Subfield: Physiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2415158650